Katherine Menson, DO
Critical Care Medicine · Burlington, VTNPI 1386986974
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,307 of the $4,434 with a category attached, or 97.1%. 3 manufacturers reported payments, led by Chiesi USA, Inc. at 59.1% of the total.
Across 9 payments — averaging $492.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$3K
- Genentech USA, Inc.$2K
- CSL Behring$13
Across 44 payments — averaging $6501.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$190K
- Chiesi USA, Inc.$75K
- AstraZeneca$22K
What the payments were for
- Travel & lodging$4,30797%
- Food & beverage$1133%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 2 | $2,619 |
| Genentech USA, Inc. | 6 | $1,802 |
| CSL Behring | 1 | $13 |
How this compares
Too few critical care medicine providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 17 | $81,900 |
| XolairOmalizumab | 26 | $74,071 |
| TezspireTezepelumab-Ekko | 14 | $61,538 |
| Dupixent PenDupilumab | 16 | $57,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $43,317 |
| DuleraMometasone/Formoterol | 54 | $25,794 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $16,304 |
| Spiriva RespimatTiotropium Bromide | 25 | $16,125 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,402 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $10,580 |
| BreynaBudesonide/Formoterol Fumarate | 22 | $7,697 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,856 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,669 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,932 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,871 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Burlington
- David KaminskyBurlington$21K
- Renee StapletonBurlington$10K
- John KlickBurlington$5K
- Katelin MorrissetteBurlington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.